Do analysts rate SPRO or ZIVO?

Spero Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 430.97%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor SPRO or ZIVO?

In the previous week, Spero Therapeutics had 8 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for Spero Therapeutics and 1 mentions for ZIVO Bioscience. Spero Therapeutics' average media sentiment score of 1.36 beat ZIVO Bioscience's score of 0.67 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ZIVO Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LONA or ZIVO?

Athira Pharma presently has a consensus target price of $17.33, indicating a potential upside of 139.41%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LONA or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer ZIVO or TLPH?

Talphera has a consensus target price of $3.00, indicating a potential upside of 152.10%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable valuation & earnings, ZIVO or TLPH?

ZIVO Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 1,090.32 -$7.78M -$1.40 N/A Talphera $1K 61,768.14 -$14.29M -$0.27 N/A

Is ZIVO or TLPH more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Talphera N/A -87.28% -51.36%

Do analysts rate ZIVO or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 593.64%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or DWTX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Dogwood Therapeutics N/A -75.55% -40.28%

Does the media prefer ZIVO or DWTX?

In the previous week, Dogwood Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for Dogwood Therapeutics and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Dogwood Therapeutics' score of 0.14 indicating that ZIVO Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ELOX or ZIVO?

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 127.40%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ELOX or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Does the media favor ELOX or ZIVO?

In the previous week, Eloxx Pharmaceuticals had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Eloxx Pharmaceuticals' score of 0.27 indicating that ZIVO Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ZIVO Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ZIVO Bioscience (ZIVO) Competitors

$4.10 0.00 (0.00%)

As of 09/14/2026

Compare

ZIVO vs. SPRO, LONA, TLPH, DWTX, and ELOX

Should you buy ZIVO Bioscience stock or one of its competitors? ZIVO Bioscience's main competitors and comparable companies include Spero Therapeutics (SPRO), Athira Pharma (LONA), Talphera (TLPH), Dogwood Therapeutics (DWTX), and Eloxx Pharmaceuticals (ELOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ZIVO Bioscience compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Spero Therapeutics had 8 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for Spero Therapeutics and 1 mentions for ZIVO Bioscience. Spero Therapeutics' average media sentiment score of 1.36 beat ZIVO Bioscience's score of 0.67 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ZIVO Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spero Therapeutics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	0.99	$8.57M	$0.11	10.27
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

Spero Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 430.97%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spero Therapeutics has a net margin of 24.90% compared to ZIVO Bioscience's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat ZIVO Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Spero Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Summary

Spero Therapeutics beats ZIVO Bioscience on 14 of the 16 factors compared between the two stocks.

How does ZIVO Bioscience compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Athira Pharma has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

Athira Pharma presently has a consensus target price of $17.33, indicating a potential upside of 139.41%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has higher revenue and earnings than Athira Pharma. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ZIVO Bioscience's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Athira Pharma's average media sentiment score of 1.89 beat ZIVO Bioscience's score of 0.67 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
ZIVO Bioscience	Positive

Summary

Athira Pharma beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to Talphera?

ZIVO Bioscience (NASDAQ:ZIVO) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

ZIVO Bioscience's return on equity of 0.00% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Talphera	N/A	-87.28%	-51.36%

In the previous week, ZIVO Bioscience and ZIVO Bioscience both had 1 articles in the media. Talphera's average media sentiment score of 1.89 beat ZIVO Bioscience's score of 0.67 indicating that Talphera is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Positive
Talphera	Very Positive

Talphera has a consensus target price of $3.00, indicating a potential upside of 152.10%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

ZIVO Bioscience has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

ZIVO Bioscience has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A
Talphera	$1K	61,768.14	-$14.29M	-$0.27	N/A

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Talphera beats ZIVO Bioscience on 9 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Dogwood Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 593.64%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ZIVO Bioscience's return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

In the previous week, Dogwood Therapeutics had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for Dogwood Therapeutics and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Dogwood Therapeutics' score of 0.14 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ZIVO Bioscience has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

ZIVO Bioscience has higher revenue and earnings than Dogwood Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ZIVO Bioscience and Dogwood Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Eloxx Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	11.59	-$5.99M	-$1.54	N/A
ZIVO Bioscience	$15.85K	1,090.32	-$7.78M	-$1.40	N/A

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 127.40%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

In the previous week, Eloxx Pharmaceuticals had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.67 beat Eloxx Pharmaceuticals' score of 0.27 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ZIVO Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.28M	$12.42B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.56%	12.21%
P/E Ratio	-0.84	789.61	272.86	25.31
Price / Sales	1,090.32	952.99	701.69	107.99
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	-5.06	10.41	10.37	6.18
Net Income	-$7.78M	$2.83B	$3.49B	$357.96M
7 Day Performance	31.73%	-1.53%	-0.76%	-0.56%
1 Month Performance	-4.45%	0.78%	-0.39%	-3.62%
1 Year Performance	-69.19%	3.91%	18.93%	6.05%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.10 flat	N/A	-69.2%	$17.28M	$15.85K	N/A	10
SPRO Spero Therapeutics	3.9776 of 5 stars	$1.14 +1.3%	N/A	-39.9%	$66.10M	$42.96M	10.32	150	News Coverage Positive News Analyst Forecast Analyst Revision
LONA Athira Pharma	3.2086 of 5 stars	$7.04 +2.6%	$17.33 +146.4%	N/A	$66.06M	N/A	N/A	40	Positive News Gap Down
TLPH Talphera	2.7747 of 5 stars	$1.26 +1.2%	$3.00 +139.0%	+21.4%	$65.15M	$30K	N/A	19	Positive News
DWTX Dogwood Therapeutics	2.4559 of 5 stars	$1.89 +0.5%	$12.00 +535.3%	-64.9%	$64.21M	N/A	N/A	5	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. SPRO, LONA, TLPH, DWTX, and ELOX

How does ZIVO Bioscience compare to Spero Therapeutics?

Summary

How does ZIVO Bioscience compare to Athira Pharma?

Summary

How does ZIVO Bioscience compare to Talphera?

Summary

How does ZIVO Bioscience compare to Dogwood Therapeutics?

Summary

How does ZIVO Bioscience compare to Eloxx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. SPRO, LONA, TLPH, DWTX, and ELOX

How does ZIVO Bioscience compare to Spero Therapeutics?

Do insiders and institutionals have more ownership in SPRO or ZIVO?

Does the media favor SPRO or ZIVO?

Which has higher earnings and valuation, SPRO or ZIVO?

Do analysts rate SPRO or ZIVO?

Is SPRO or ZIVO more profitable?

Which has more volatility & risk, SPRO or ZIVO?

Summary

How does ZIVO Bioscience compare to Athira Pharma?

Which has more risk & volatility, LONA or ZIVO?

Do analysts rate LONA or ZIVO?

Which has higher earnings and valuation, LONA or ZIVO?

Do institutionals and insiders believe in LONA or ZIVO?

Is LONA or ZIVO more profitable?

Does the media favor LONA or ZIVO?

Summary

How does ZIVO Bioscience compare to Talphera?

Is ZIVO or TLPH more profitable?

Does the media prefer ZIVO or TLPH?

Do analysts prefer ZIVO or TLPH?

Which has more volatility and risk, ZIVO or TLPH?

Which has preferable valuation & earnings, ZIVO or TLPH?

Do institutionals & insiders have more ownership in ZIVO or TLPH?

Summary

How does ZIVO Bioscience compare to Dogwood Therapeutics?

Do analysts rate ZIVO or DWTX?

Is ZIVO or DWTX more profitable?

Does the media prefer ZIVO or DWTX?

Which has more risk & volatility, ZIVO or DWTX?

Which has stronger earnings and valuation, ZIVO or DWTX?

Do institutionals and insiders hold more shares of ZIVO or DWTX?

Summary

How does ZIVO Bioscience compare to Eloxx Pharmaceuticals?

Which has better earnings and valuation, ELOX or ZIVO?

Do analysts rate ELOX or ZIVO?

Is ELOX or ZIVO more profitable?

Does the media favor ELOX or ZIVO?

Do institutionals & insiders have more ownership in ELOX or ZIVO?

Which has more risk and volatility, ELOX or ZIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools